455 Mission Bay Boulevard South
Tel: 415-482-5300, Toll Free 855-482-NKTR (6587)
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
416 articles with Nektar Therapeutics
Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.-based financial markets.
RedHill Biopharma Ltd. today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. resolving their patent litigation.
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO).
The Biotech Bay region is home to 3,418 life sciences companies, and 96,574 employees making an average of $151,076.
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native IL-2 designed to selectively stimulate T regulatory (Treg) cell function
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)
-- Results demonstrate NKTR-255's differentiated pharmacologic profile versus precomplexed IL-15 agonists, supporting its potential as a potent immunotherapy agent --
London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund's original target was just at $350 million.
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2021.
Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2021 on Thursday, May 6, 2021, after the close of U.S.-based financial markets.
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020.
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the fourth quarter and year-ended December 31, 2020, on Thursday, February 25, 2021, after the close of U.S.-based financial markets.
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cancer and auto-immune disease, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada ) for a Phase 2/3 study of bempegaldesleukin (NKTR-214, BEMPEG)
Nektar Therapeutics has entered into a financing and co-development collaboration with SFJ Pharmaceuticals which will advance the development of investigational CD122-preferential IL-2–pathway agonist bempegaldesleukin for head and neck cancer.
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 11:50 a.m. Pacific Time . The presentation and Q&A session will be accessible via a Webcast through a link poste
Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately.
Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million
Nektar Therapeutics (NASDAQ: NKTR) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its royalties on future sales of ADYNOVATE, under Nektar's agreement with Baxalta Incorporated, a Takeda company, and MOVANTIK, under Nektar's agreement with AstraZeneca AB. Under the terms of th
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
Nektar Therapeutics (NASDAQ:NKTR) today announced that the first patient has been dosed in the Phase 1/2 trial of NKTR-255, Nektar's investigational IL-15 pathway agonist, in patients with relapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC) at the START Center for Cancer Care in San Antonio, TX.
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
Nektar Therapeutics (NASDAQ: NKTR) today announced two nonclinical data presentations for NKTR-255, its IL-15 pathway agonist, at the 62 nd American Society of Hematology (ASH) Annual Meeting. The presentations include an oral presentation of translational research studies conducted in collaboration with researchers from Dana-Farbe